5-Hydroxytryptofán (5-HTP)

5-HTP je prekurzorom serotonínu. Serotonín je neurotransmiter, ktorý pôsobí ako anti-depresívum a považuje sa za “hormón šťastia”. 5-HTP je jednoduchý spôsob, ako zvýšiť hladiny serotonínu v mozgu, pretože obchádza mechanizmus obmedzujúci rýchlosť jeho tvorby. Užívatelia žnú buď odmeny alebo riziká vyplývajúce so zvýšeného množstva serotonínu v mozgu.

AKA
retinol, retinal, retinoic acid, tretinoin, beta-karotén

Zhrnutie

5-HTP je zlúčenina, ktorá sa v mozgu premieňa na serotonín. Serotonín je jedným z hlavných neurotransmiterov podieľajúcich sa na šťastí a potláčajúci depresiu.

5-HTP sa úspešne používa na obnovenie hladín serotonínu u ľudí, ktorí môžu trpieť zníženými hladinami serotonínu (napr. ľudia trpiaci depresiou a ľudia s vysokými hladinami zápalu v tele – typické pri metabolickom syndróme.

Ako užívať

Dávka 5-HTP je v rozmedzí 300-500 mg a užíva sa buď raz denne alebo v rozdelených dávkach. Nižšie dávky môžu byť tiež účinné, aj keď zvyčajne v kombinácii s inými látkami.

Na účely zníženia príjmu potravy sa má 5-HTP užívať spolu s jedlom, pretože zvyšuje pocit sýtosti z príjmu potravy (namiesto znižovania chuti do jedla/hladu).

5-HTP by sa nemal užívať s iným neurologickým liekom, ktorý bol predpísaný na antidepresívne alebo iné kognitívne účely, pokiaľ to nenariadi lekár. Toto je najdôležitejšie pri užívaní SSRI (Selektívne inhibítory spätného vychytávania sérotonínu), kde kombinácia s 5-HTP je potenciálne smrteľná.

Upozornenie

Hoci toxicita serotonínu nebola u ľudí pozorovaná, pri súbežnom požití 5-HTP a antidepresív sa odporúča poradiť sa s lekárom. 5-HTP je nervovo aktívny. Zvýšenie hladiny serotonínu sa prejavuje viac „euforicky“ alebo zvýšením pocitu šťastia, ako stimulačne.

Literatúra

Jukić T, et al. The use of a food supplementation with D-phenylalanine, L-glutamine and L-5-hydroxytriptophan in the alleviation of alcohol withdrawal symptoms. Coll Antropol. (2011)
Rondanelli M, et al. Satiety and amino-acid profile in overweight women after a new treatment using a natural plant extract sublingual spray formulation. Int J Obes (Lond). (2009)
Rondanelli M, et al. Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration. Eat Weight Disord. (2012)
Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther. (2006)
Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. (1998)
The Metabolism of L-Tryptophan by Isolated Rat Liver Cells.
Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan.
O’Neil MF, Moore NA. Animal models of depression: are there any. Hum Psychopharmacol. (2003)
Ceci F, et al. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. J Neural Transm. (1989)
Cangiano C, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. Int J Obes Relat Metab Disord. (1998)
Cangiano C, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr. (1992)
Cangiano C, et al. Effects of 5-hydroxytryptophan on eating behavior and adherence to dietary prescriptions in obese adult subjects. Adv Exp Med Biol. (1991)
Precursor control of Neurotransmitter Synthesis.
Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. Obes Res. (1995)
Routh VH, Stern JS, Horwitz BA. Serotonergic activity is depressed in the ventromedial hypothalamic nucleus of 12-day-old obese Zucker rats. Am J Physiol. (1994)
Total and Free tryptophan concentration in the plasma of depressive patients.
Decreased plasma tryptophan levels in major depression.
Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. (1991)
Myint AM, Kim YK. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses. (2003)
Transcriptional activation of Indoleamine Dioxygenase by Interleukin 1 and Tumor Necrosis Factor α in Interferon-Treated Epithelial Cells.
The phenomenology and treatment of interferon-induced depression.
Bonaccorso S, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. (2002)
Shaw K, Turner J, Del Mar C. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Aust N Z J Psychiatry. (2002)
van Hiele LJ. l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with ‚therapy-resistant‘ depressions. Neuropsychobiology. (1980)
Hinz M, Stein A, Uncini T. 5-HTP efficacy and contraindications. Neuropsychiatr Dis Treat. (2012)
Hinz M, Stein A, Uncini T. Amino acid management of Parkinson’s disease: a case study. Int J Gen Med. (2011)
Hinz M, Stein A, Uncini T. Monoamine depletion by reuptake inhibitors. Drug Healthc Patient Saf. (2011)
Shell W, et al. A randomized, placebo-controlled trial of an amino acid preparation on timing and quality of sleep. Am J Ther. (2010)
Emanuele E, et al. An open-label trial of L-5-hydroxytryptophan in subjects with romantic stress. Neuro Endocrinol Lett. (2010)
Speroff L, et al. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. (2008)
Stearns V, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. (2005)
Freedman RR. Treatment of menopausal hot flashes with 5-hydroxytryptophan. Maturitas. (2010)
Freedman RR, Wasson S. Miniature hygrometric hot flash recorder. Fertil Steril. (2007)
Park SB, et al. Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology. (1994)
Oldman A, et al. Biochemical and behavioural effects of acute tryptophan depletion in abstinent bulimic subjects: a pilot study. Psychol Med. (1995)
Cleare AJ, Bond AJ. The effect of tryptophan depletion and enhancement on subjective and behavioural aggression in normal male subjects. Psychopharmacology (Berl). (1995)
Klaassen T, et al. Effects of tryptophan depletion on anxiety and on panic provoked by carbon dioxide challenge. Psychiatry Res. (1998)
Miller HE, Deakin JF, Anderson IM. Effect of acute tryptophan depletion on CO2-induced anxiety in patients with panic disorder and normal volunteers. Br J Psychiatry. (2000)
Schruers K, et al. Effects of tryptophan depletion on carbon dioxide provoked panic in panic disorder patients. Psychiatry Res. (2000)
Schruers K, et al. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res. (2002)
Maron E, et al. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J Psychopharmacol. (2004)
Bruni O, et al. L -5-Hydroxytryptophan treatment of sleep terrors in children. Eur J Pediatr. (2004)
Schruers K, et al. L-5-hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. Psychopharmacology (Berl). (2002)
Stamford JA, Kruk ZL, Millar J. Striatal dopamine terminals release serotonin after 5-HTP pretreatment: in vivo voltammetric data. Brain Res. (1990)
Zhelyaskov DK, Levitt M, Udenfriend S. Tryptophan derivatives as inhibitors of tyrosine hydroxylase in vivo and in vitro. Mol Pharmacol. (1968)
Awazi N, Guldberg HC. On the interaction of 5-hydroxytryptophan and 5-hydroxytryptamine with dopamine metabolism in the rat striatum. Naunyn Schmiedebergs Arch Pharmacol. (1978)
Breier JM, Bankson MG, Yamamoto BK. L-tyrosine contributes to (+)-3,4-methylenedioxymethamphetamine-induced serotonin depletions. J Neurosci. (2006)
Correlation between brain tryptophan and plasma neutral amino acid levels following food consumption in rats.
Ritvo ER, et al. Effects of L-dopa in autism. J Autism Child Schizophr. (1971)
Karobath M, Díaz JL, Huttunen MO. The effect of L-dopa on the concentrations of tryptophan, tyrosine and serotonin in rat brain. Eur J Pharmacol. (1971)
Borah A, Mohanakumar KP. Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol. (2007)
van Praag HM. In search of the mode of action of antidepressants. 5-HTP/tyrosine mixtures in depressions. Neuropharmacology. (1983)
Henman FD. Amino acid decarboxylase enzymes–vital or irrelevant to gastric secretion. Digestion. (1975)
Orlefors H, et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging. (2006)
Bertoldi M, Gonsalvi M, Voltattorni CB. Green tea polyphenols: novel irreversible inhibitors of dopa decarboxylase. Biochem Biophys Res Commun. (2001)
Gustafsson BI, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation. (2005)
Aliño JJ, Gutierrez JL, Iglesias ML. 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study. Int Pharmacopsychiatry. (1976)
Kline N, Sacks W. Treatment of depression with an mao inhibitor followed by 5-HTP–an unfinished research project. Acta Psychiatr Scand Suppl. (1980)
Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol. (1996)
Comparison of the Antidepressant Action of Tryptophan, Tryptophan/5-Hydroxytryptophan Combination and Nomifensine.
Nardini M, et al. Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study. Int J Clin Pharmacol Res. (1983)
van der Horst-Schrivers AN, et al. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours. Eur J Cancer. (2007)
Joy T, et al. Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake. Can J Gastroenterol. (2008)

Medicínske upozornenie!